[Hospital intensive monitoring of adverse reactions of ACE inhibitors].
OBJECTIVE
Angiotensin II converting enzyme (ACE) inhibitors represent one of the most important pharmacological instruments for the treatment of arterial hypertension and are currently also used for other cardiovascular indications. The actions of ACE-inhibitors mainly depends on blocking the ACE enzyme in the renin-angiotensin-aldosterone system. However, the ACE enzyme also has a kinase activity. The inhibition of this enzyme may also cause an accumulation of tissue mediators (bradykinin) responsible for a number of adverse reactions.


METHODS
An intensive hospital monitoring programme of adverse reactions to drugs, known as MIO[symbol: see text]'96, was carried out by the Centre of Pharmacoepidemiology of the Faculty of Medicine and Surgery at the Second University of Naples during the period 25 March-18 April 1996. The main aims of the programme were to highlight the incidence of adverse reactions to the drugs monitored and the definition of the risk/benefit ratio taking account of the main physiological and pathophysiological variations of patients. This paper reports the results of the programme of adverse effects correlated to the use of ACE-inhibitors. A total of 175 records were compiled for 105 patients receiving antihypertensive treatment with a number of ACE-inhibitors (captopril, enalapril, lisinopril); a very high mean incidence of adverse events was documented (22%) without any severe undesirable effects.


RESULTS
The following adverse events were documented (the cumulative incidence is given in brackets): dysgeusia (17%), flush (8%), headache (33%), exanthema (17%), diarrhoea (8%), vertigo (8%), xerostomia (8%). Coughing was not reported in any patient.


CONCLUSIONS
Further periods of intensive monitoring will be required to obtain a greater quantity of data from the Intensive Monitoring of adverse events through the MIO[symbol: see text]'97 programme.
Istituto di Farmacologia e Tossicologia, Facoltà di Medicina e Chirurgia, Seconda Università degli Studi di Napoli.
M
M
Mangrella
G
G
Motola
F
F
Russo
F
F
Mazzeo
T
T
Giassa
G
G
Falcone
F
F
Rossi
O
O
D'Alessio
F
F
Rossi
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects*; D000959:Antihypertensive Agents / Q000009:adverse effects*; D002216:Captopril / Q000009:adverse effects; D002316:Cardiotonic Agents / Q000009:adverse effects; D003625:Data Collection; D016903:Drug Monitoring; D004656:Enalapril / Q000009:adverse effects; D006761:Hospitals; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007558:Italy; D017706:Lisinopril / Q000009:adverse effects; D012084:Renin-Angiotensin System / Q000187:drug effects; D018570:Risk Assessment
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002316:Cardiotonic Agents; D004656:Enalapril; D002216:Captopril; D017706:Lisinopril